Personalized antiplatelet therapy;Tratamiento antiagregante plaquetario personalizado

Revista Espanola de Cardiologia

Volumn 67, Issue 6, 2014, Pages 480-487

  Gurbel, Paul A ^a   Rafeedheen, Rahil ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Genotyping; Personalized antiplatelet therapy; Platelet function testing; Thrombosis

Indexed keywords

CLOPIDOGREL;

ARTICLE; PERSONALIZED MEDICINE; THROMBOCYTE FUNCTION;

EID: 84901621062     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2014.01.013     Document Type: Article

References (60)

1. P.A. Gurbel, and U.S. Tantry Combination antithrombotic therapies Circulation 121 2010 569 583
2. U.S. Tantry, L. Bonello, D. Aradi, M.J. Price, Y.H. Jeong, D.J. Angiolillo Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
3. U.S. Tantry, E. Mahla, M.G. Gesheff, and P.A. Gurbel Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account Expert Rev Cardiovasc Ther 11 2013 1547 1556
4. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287 discussion 1287
5. U.S. Tantry, Y.H. Jeong, E.P. Navarese, J. Kubica, and P.A. Gurbel Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease Expert Rev Cardiovasc Ther 11 2013 447 462
6. A.L. Beitelshees, R.B. Horenstein, M.R. Vesely, M.R. Mehra, and A.R. Shuldiner Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions Clin Pharmacol Ther 89 2011 455 459
7. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
8. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 855
9. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
10. G. Pare, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
11. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
12. M.J. Price, U.S. Tantry, and P.A. Gurbel The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors Rev Cardiovasc Med 12 2011 1 12
13. ® [package insert] [citado 10 Ene 2014]. Disponible en: www.Plavix.com
14. A.L. Frelinger 3rd, D.L. Bhatt, R.D. Lee, D.J. Mulford, J. Wu, and S. Nudurupati et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function J Am Coll Cardiol 61 2013 872 879
15. W.C. Lau, P.A. Gurbel, P.B. Watkins, C.J. Neer, A.S. Hopp, and D.G. Carville et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
16. W.C. Lau, T.D. Welch, T. Shields, M. Rubenfire, U.S. Tantry, and P.A. Gurbel The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity J Cardiovasc Pharmacol 57 2011 86 93
17. P.A. Gurbel, K.P. Bliden, D.K. Logan, D.J. Kereiakes, K.C. Lasseter, and A. White et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: The PARADOX Study J Am Coll Cardiol 62 2013 505 512
18. P.A. Gurbel, T.D. Nolin, and U.S. Tantry Clopidogrel efficacy and cigarette smoking status JAMA 307 2012 2495 2496
19. W.C. Lau, L.A. Waskell, P.B. Watkins, C.J. Neer, K. Horowitz, and A.S. Hopp et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
20. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
21. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
22. P.A. Gurbel, E.M. Ohman, Y.H. Jeong, and U.S. Tantry Toward a therapeutic window for antiplatelet therapy in the elderly Eur Heart J 33 2012 1187 1189
23. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, and B. Cercek et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
24. H. Jneid, J.L. Anderson, R.S. Wright, C.D. Adams, C.R. Bridges, and D.E. Casey Jr. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
25. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
26. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
27. D. Trenk, G.W. Stone, M. Gawaz, A. Kastrati, D.J. Angiolillo, and U. Müller et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
28. J.P. Collet, T. Cuisset, G. Rangé, G. Cayla, S. Elhadad, C. Pouillot ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
29. P.A. Gurbel, and U.S. Tantry An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial JAMA 305 2011 1136 1137
30. J.L. Mega, W. Hochholzer, A.L. Frelinger 3rd, M.J. Kluk, D.J. Angiolillo, and D.J. Kereiakes et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
31. M.J. Price, D.J. Angiolillo, P.S. Teirstein, E. Lillie, S.V. Manoukian, and P.B. Berger et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial Circulation 124 2011 1132 1137
32. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
33. L. Bonello, L. Camoin-Jau, S. Armero, O. Com, S. Arques, and C. Burignat-Bonello et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
34. G. Campo, L. Fileti, N. De Cesare, E. Meliga, A. Furgieri, F. Russo 3T/2R Investigators Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) trial substudy J Am Coll Cardiol 56 2010 1447 1455
35. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, J.P. Mouret, and L. Bali et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study J Am Coll Cardiol Interven 1 2008 649 653
36. G.W. Stone, B. Witzenbichler, G. Weisz, M.J. Rinaldi, F.J. Neumann, and D.C. Metzger et al. ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
37. A. Kirtane New insights into high platelet reactivity and the existence of a therapeutic window: ADAPT-DES at 2 years Presented at TCT 2013 [citado 24 Ene 2014] 2014 Disponible en: http://www.tctconference.com/about-tct/faculty. html?task=lecturer&sid= 2146
38. T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, and K. Dietz et al. The Residual Platelet Aggregation After Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
39. P. Fontana, P. Berdagué, C. Castelli, S. Nolli, I. Barazer, and P. Fabbro-Peray et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study J Thromb Haemost 8 2010 2614 2623
40. G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, and M. Miccoli et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 474 483
41. D. Sibbing, S. Schulz, S. Braun, T. Morath, J. Stegherr, and J. Mehilli et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
42. P.A. Gurbel, K.P. Bliden, I.A. Navickas, E. Mahla, J. Dichiara, and T.A. Suarez et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events Am Heart J 160 2010 346 354
43. L. Bonello, J. Mancini, M. Pansieri, L. Maillard, P. Rossi, and F. Collet et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel J Thromb Haemost 10 2012 1999 2005
44. J. Doll, E. Zeitler, and R. Becker Generic clopidogrel: time to substitute? JAMA 310 2013 145 146
45. R. Marcucci, R. Paniccia, A.M. Gori, G.F. Gensini, and R. Abbate Bioequivalence in the real world is a complex challenge: the case of clopidogrel J Am Coll Cardiol 61 2013 594 595
46. C.Y. Shim, S. Park, J.W. Song, S.H. Lee, J.S. Kim, and N. Chung Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study Clin Ther 32 2010 1664 1673
47. A.R. Khosravi, M. Pourmoghadas, M. Ostovan, G.K. Mehr, M. Gharipour, and H. Zakeri et al. The impact of generic form of clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study J Res Med Sci 16 2011 640 650
48. D. Caldeira, R.M. Fernandes, J. Costa, C. David, C. Sampaio, and J.J. Ferreira Branded versus generic clopidogrel in cardiovascular diseases: a systematic review J Cardiovasc Pharmacol 61 2013 277 282
49. N. Sambu, A. Radhakrishnan, and N. Curzen A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel J Cardiovasc Pharmacol 60 2012 495 501
50. J.C. Kovacic, R. Mehran, J. Sweeny, J.R. Li, P. Moreno, and U. Baber et al. Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel J Cardiovasc Pharmacol Ther 19 2014 201 208
51. R. Wahi, G. Rao, I. Thethi, and L. Pathak Prevalence of free methyl chloride as an impurity in generic clopidogrel preparations. Safety implications in cardiovascular patients Circulation 122 2010 A 17290
52. A.A. Heestermans, J.W. Van Werkum, D. Taubert, T.H. Seesing, N. Von Beckerath, and C.M. Hackeng Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
53. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K.C. Theodoropoulos, and G. Makris et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 6 2012 797 804
54. G. Parodi, R. Valenti, B. Bellandi, A. Migliorini, R. Marcucci, and V. Comito et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
55. E.L. Hobl, T. Stimpfl, J. Ebner, C. Schoergenhofer, U. Derhaschnig, and R. Sunder-Plassmann et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double blind, placebo-controlled trial J Am Coll Cardiol 63 2014 630 635
56. L. Chen, A.W. Bracey, R. Radovancevic, J.R. Cooper Jr., C.D. Collard, and W.K. Vaughn et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting J Thorac Cardiovasc Surg 128 2004 425 431
57. E. Mahla, T.A. Suarez, K.P. Bliden, P. Rehak, H. Metzler, and A.J. Sequeira et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study Circ Cardiovasc Interv 5 2012 261 269
58. Y.L. Kwak, J.C. Kim, Y.S. Choi, K.J. Yoo, Y. Song, and J.K. Shim Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery J Am Coll Cardiol 56 2010 1994 2002
59. M. Ranucci, E. Baryshnikova, G. Soro, A. Ballotta, D. De Benedetti, and D. Conti Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines Ann Thorac Surg 91 2011 123 129
60. V.A. Ferraris, S.P. Saha, J.H. Oestreich, H.K. Song, T. Rosengart, and T.B. Reece et al. Society of Thoracic Surgeons 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations Ann Thorac Surg 94 2012 1761 1781